|
|
 Previous Article | Table of Contents | Next Article 
High CD34+ Cell Counts Decrease Hematologic Toxicity of
Autologous Peripheral Blood Progenitor Cell Transplantation
Nicolas Ketterer,
Gilles Salles,
Michel Raba,
Daniel Espinouse,
Anne Sonet,
Pierre Tremisi,
Charles Dumontet,
Isabelle Moullet,
Assia Eljaafari-Corbin,
Eve-Marie Neidhardt-Berard,
Fadhela Bouafia, and
Bertrand Coiffier
From the Service d'Hématologie, Centre Hospitalier Lyon-Sud,
Hospices Civils de Lyon and UPRES-JE 1879 "Hémopathies
Lymphoïdes malignes", Université Claude Bernard,
Pierre-Bénite; and Etablissement de Transfusion Sanguine de Lyon,
Lyon, France.
Optimal numbers of CD34+ cells to be reinfused in
patients undergoing peripheral blood progenitor cell (PBPC)
transplantation after high-dose chemotherapy are still unknown.
Hematologic reconstitution of 168 transplantations performed in
patients with lymphoproliferative diseases was analyzed according to
the number of CD34+ cells reinfused. The number of days
from PBPC reinfusion until neutrophil recovery (>1.0 × 109/L) and unsustained platelet recovery (>50 × 109/L) were analyzed in three groups defined by the number
of CD34+ cells reinfused: a low group with less than or
equal to 2.5 × 106 CD34+ cells/kg, a high
group with greater than 15 × 106 CD34+
cells/kg, and an intermediate group to which the former two groups were
compared. The 22 low-group patients had a significantly delayed neutrophil (P < .0001) and platelet recovery (P < .0001). The 41 high-group patients experienced significantly shorter
engraftment compared with the intermediate group with a median of 11 (range, 8 to 16) versus 12 (range, 7 to 17) days for neutrophil
recovery (P = .003), and a median of 11 (range, 7 to 24)
versus 14 (range, 8 to 180+) days for platelet recovery (P < .0001). These patients required significantly less platelet
transfusions (P = .002). In a multivariate analysis, the
amount of CD34+ cells reinfused was the only variable
showing significance for neutrophil and platelet recovery. High-group
patients had a shorter hospital stay (P = .01) and tended to
need fewer days of antibotic administration (P = .12). In
conclusion, these results suggest that reinfusion of greater than 15 × 106 CD34+ cells/kg after high-dose
chemotherapy for lymphoproliferative diseases further shortens
hematopoietic reconstitution, reduces platelet requirements, and may
improve patients' quality of life.
Blood, Vol. 91 No. 9 (May 1), 1998:
pp. 3148-3155
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Y. H. Leung and Y.-L. Kwong
Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies
Br. Med. Bull.,
November 8, 2009;
(2009)
ldp040v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Flomenberg, S. M. Devine, J. F. DiPersio, J. L. Liesveld, J. M. McCarty, S. D. Rowley, D. H. Vesole, K. Badel, and G. Calandra
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
Blood,
September 1, 2005;
106(5):
1867 - 1874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Straka, F. Oduncu, A. Hinke, H. Einsele, E. Drexler, B. Schnabel, L. Arseniev, J. Walther, A. Konig, and B. Emmerich
Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients
Blood,
October 1, 2004;
104(7):
1989 - 1994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mineishi, T. Saito, Y. Kanda, R. Tanosaki, K. Tobinai, and Y. Takaue
Delayed Recovery of Neutrophil Counts After Peripheral Stem Cell Transplantation Which Improved with Administration of a Minimal Dose of G-CSF: A Case Report
Jpn. J. Clin. Oncol.,
January 1, 2001;
31(1):
43 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. McNiece, R. Jones, S. I. Bearman, P. Cagnoni, Y. Nieto, W. Franklin, J. Ryder, A. Steele, J. Stoltz, P. Russell, et al.
Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer
Blood,
November 1, 2000;
96(9):
3001 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1360 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
